Definium Therapeutics, Inc.

NasdaqGS:DFTX Stock Report

Market Cap: US$1.5b

Definium Therapeutics Valuation

Is DFTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of DFTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: DFTX ($15.05) is trading below our estimate of fair value ($234.95)

Significantly Below Fair Value: DFTX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DFTX?

Key metric: As DFTX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for DFTX. This is calculated by dividing DFTX's market cap by their current book value.
What is DFTX's PB Ratio?
PB Ratio11.4x
BookUS$130.60m
Market CapUS$1.52b

Price to Book Ratio vs Peers

How does DFTX's PB Ratio compare to its peers?

The above table shows the PB ratio for DFTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
COLL Collegium Pharmaceutical
5.2x39.83%US$1.5b
INVA Innoviva
1.4x10.78%US$1.5b
TRVI Trevi Therapeutics
7.1x42.77%US$1.4b
ELVN Enliven Therapeutics
3.3x-8.83%US$1.5b
DFTX Definium Therapeutics
11.4x51.97%US$1.5b

Price-To-Book vs Peers: DFTX is expensive based on its Price-To-Book Ratio (11.4x) compared to the peer average (4.3x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does DFTX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

21 CompaniesPrice / BookEstimated GrowthMarket Cap
PLRX Pliant Therapeutics
0.4x0.21%US$78.66m
HYPD Hyperion DeFi
0.4x97.80%US$28.13m
CTXR Citius Pharmaceuticals
0.3x47.75%US$17.78m
KPRX Kiora Pharmaceuticals
0.4x61.14%US$8.03m
DFTX 11.4xIndustry Avg. 2.6xNo. of Companies21PB01.63.24.86.48+
21 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: DFTX is expensive based on its Price-To-Book Ratio (11.4x) compared to the US Pharmaceuticals industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is DFTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DFTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio11.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DFTX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DFTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$15.05
US$28.67
+90.48%
48.28%US$61.00US$16.00n/a12
Jan ’27US$13.39
US$28.67
+114.09%
48.28%US$61.00US$16.00n/a12
Dec ’26US$12.26
US$25.64
+109.11%
40.10%US$55.00US$16.00n/a11
Nov ’26US$14.20
US$24.91
+75.42%
42.61%US$55.00US$16.00n/a11
Oct ’26US$12.33
US$23.78
+92.84%
47.90%US$55.00US$16.00n/a9
Sep ’26US$8.88
US$25.00
+181.53%
45.64%US$55.00US$16.00n/a10
Aug ’26US$8.44
US$24.50
+190.28%
46.97%US$55.00US$16.00n/a10
Jul ’26US$6.68
US$24.50
+266.77%
46.97%US$55.00US$16.00n/a10
Jun ’26US$7.26
US$24.50
+237.47%
46.97%US$55.00US$16.00n/a10
May ’26US$6.59
US$24.50
+271.78%
46.97%US$55.00US$16.00n/a10
Apr ’26US$5.54
US$24.50
+342.24%
46.97%US$55.00US$16.00n/a10
Mar ’26US$6.72
US$25.60
+280.95%
43.61%US$55.00US$16.00n/a10
Feb ’26US$6.79
US$25.60
+277.03%
43.61%US$55.00US$16.00n/a10
Jan ’26US$6.96
US$25.89
+271.97%
45.32%US$55.00US$16.00US$13.399
Dec ’25US$8.17
US$26.63
+225.89%
46.00%US$55.00US$16.00US$12.268
Nov ’25US$6.14
US$26.25
+327.52%
47.76%US$55.00US$14.00US$14.208
Oct ’25US$5.63
US$26.25
+366.25%
47.76%US$55.00US$14.00US$12.338
Sep ’25US$6.06
US$26.50
+337.29%
46.45%US$55.00US$16.00US$8.888
Aug ’25US$8.38
US$24.25
+189.38%
29.50%US$36.00US$16.00US$8.448
Jul ’25US$7.07
US$24.25
+243.00%
29.50%US$36.00US$16.00US$6.688
Jun ’25US$8.80
US$24.25
+175.57%
29.50%US$36.00US$16.00US$7.268
May ’25US$9.43
US$30.86
+227.22%
61.99%US$75.00US$16.00US$6.597
Apr ’25US$9.52
US$32.67
+243.14%
61.52%US$75.00US$16.00US$5.546
Mar ’25US$6.23
US$26.17
+320.01%
87.38%US$75.00US$8.00US$6.726
Feb ’25US$4.09
US$26.00
+535.70%
88.27%US$75.00US$8.00US$6.796
Jan ’25US$3.66
US$26.00
+610.38%
88.27%US$75.00US$8.00US$6.966
US$28.67
Fair Value
47.5% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/16 11:46
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Definium Therapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Christopher ChenBaird
null nullBaird